antigen-presenting cells

出典: meddic

抗原提示細胞 APCs

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2012/12/17 13:46:18」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Activation of B cells by a dendritic cell-targeted oral vaccine.
  • Sahay B, Owen JL, Yang T, Zadeh M, Lightfoot YL, Ge JW, Mohamadzadeh M1.Author information 1Department of Infectious Diseases & Pathology, Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, University of Florida, 2015 SW16th Ave, Building 1017, Room: V3-149, Gainesville, FL 32608, USA. m.zadeh@ufl.edu.AbstractProduction of long-lived, high affinity humoral immunity is an essential characteristic of successful vaccination and requires cognate interactions between T and B cells in germinal centers. Within germinal centers, specialized T follicular helper cells assist B cells and regulate the antibody response by mediating the differentiation of B cells into memory or plasma cells after exposure to T cell-dependent antigens. It is now appreciated that local immune responses are also essential for protection against infectious diseases that gain entry to the host by the mucosal route; therefore, targeting the mucosal compartments is the optimum strategy to induce protective immunity. However, because the gastrointestinal mucosae are exposed to large amounts of environmental and dietary antigens on a daily basis, immune regulatory mechanisms exist to favor tolerance and discourage autoimmunity at these sites. Thus, mucosal vaccination strategies must ensure that the immunogen is efficiently taken up by the antigen presenting cells, and that the vaccine is capable of activating humoral and cellular immunity, while avoiding the induction of tolerance. Despite significant progress in mucosal vaccination, this potent platform for immunotherapy and disease prevention must be further explored and refined. Here we discuss recent progress in the understanding of the role of different phenotypes of B cells in the development of an efficacious mucosal vaccine against infectious disease.
  • Current pharmaceutical biotechnology.Curr Pharm Biotechnol.2014 Nov;14(10):867-77.
  • Production of long-lived, high affinity humoral immunity is an essential characteristic of successful vaccination and requires cognate interactions between T and B cells in germinal centers. Within germinal centers, specialized T follicular helper cells assist B cells and regulate the antibody respo
  • PMID 24372255
  • Expression of aberrant HLA-B27 molecules is dependent on B27 dosage and peptide supply.
  • McHugh K1, Rysnik O, Kollnberger S, Shaw J, Utriainen L, Al-Mossawi MH, Payeli S, Marroquin O, Milling S, Renner C, Bowness P.Author information 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, , Oxford, UK.AbstractOBJECTIVES: Cellular expression of non-classical forms of human leukocyte antigen (HLA)-B27 (NC-B27) may be involved in spondyloarthritis (SpA) pathogenesis. We used a novel B27-specific monoclonal antibody, HD6, to ask if B27 transgenic (TG) rat splenocytes express these NC-B27 molecules. We also investigated whether B27-binding peptides could affect the expression and functional immune recognition of HD6-reactive B27 molecules.
  • Annals of the rheumatic diseases.Ann Rheum Dis.2014 Apr 1;73(4):763-70. doi: 10.1136/annrheumdis-2012-203080. Epub 2013 Apr 26.
  • OBJECTIVES: Cellular expression of non-classical forms of human leukocyte antigen (HLA)-B27 (NC-B27) may be involved in spondyloarthritis (SpA) pathogenesis. We used a novel B27-specific monoclonal antibody, HD6, to ask if B27 transgenic (TG) rat splenocytes express these NC-B27 molecules. We also i
  • PMID 23625978
  • Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.
  • Jaini R1, Rayman P, Cohen PA, Finke JH, Tuohy VK.Author information 1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.AbstractSunitinib, a protein tyrosine kinase inhibitor is the frontline therapy for renal and gastrointestinal cancers. We hypothesized that by virtue of its well documented tumor apoptosis and immune adjuvant properties, combination of Sunitinib with anti-tumor immunotherapeutics will provide synergistic inhibition of tumor growth. Our study was designed to evaluate the impact of Sunitinib on immunotherapy mediated anti-tumor immune responses and evaluate its efficacy as a combinatorial therapy with tumor targeted immunotherapeutic vaccination. Mice immunized with recombinant α-lactalbumin, a lactation protein expressed on majority of breast tumors were treated with 1 mg of Sunitinib for seven consecutive days beginning (1) concurrently, on the day of α-lactalbumin immunization or (2) sequentially, on day 9 after immunization. Ten-day lymph nodes or 21 day spleens were tested by ELISPOT assays and flow cytometry to evaluate responsiveness to α-lactalbumin immunization in presence of Sunitinib and distribution of cells involved in T cell antigen priming and proliferation in different lymphoid compartments. In addition, therapeutic efficacy of the α-lactalbumin/ Sunitinib combination was evaluated by monitoring tumor growth in the 4T1 transplanted tumor model. Our studies reveal that concurrent administration of Sunitinib with active vaccination against a targeted tumor antigen inhibits priming to the immunogen due to a drastic decrease in CD11b+CD11c+ antigen presenting cells, leading to failure of vaccination. However, sequential delivery of Sunitinib timed to avoid the priming phase of vaccination results in the desired vaccination mediated boost in immune responses.
  • International journal of cancer. Journal international du cancer.Int J Cancer.2014 Apr 1;134(7):1695-705. doi: 10.1002/ijc.28488. Epub 2013 Oct 8.
  • Sunitinib, a protein tyrosine kinase inhibitor is the frontline therapy for renal and gastrointestinal cancers. We hypothesized that by virtue of its well documented tumor apoptosis and immune adjuvant properties, combination of Sunitinib with anti-tumor immunotherapeutics will provide synergistic i
  • PMID 24105638

和文文献

  • Comparing spatial expression dynamics of bovine blastocyst under three different procedures : in-vivo, in-vitro derived, and somatic cell nuclear transfer embryos
  • Anti-TIM-3 Antibody Prevents Lymphocyte Apoptosis and Enhances Dendritic Cell Cancer Therapy
  • A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant

関連リンク

An antigen-presenting cell (APC) or accessory cell is a cell that displays foreign antigen complexes with major histocompatibility complex (MHC) on their surfaces . T-cells may recognize these complexes using their T-cell receptors (TCRs).

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元抗原提示細胞
関連記事cell」「antigen

抗原提示細胞」

  [★]

antigen presenting cell, APC, antigen-presenting cell, antigen-presenting cells, APCs


特徴

抗原提示細胞


cell」

  [★] 細胞

WordNet   license wordnet

「small room in which a monk or nun lives」
cubicle

WordNet   license wordnet

「a device that delivers an electric current as the result of a chemical reaction」
electric cell

WordNet   license wordnet

「a room where a prisoner is kept」
jail cell, prison cell

WordNet   license wordnet

「(biology) the basic structural and functional unit of all organisms; they may exist as independent units of life (as in monads) or may form colonies or tissues as in higher plants and animals」

WordNet   license wordnet

「any small compartment; "the cells of a honeycomb"」

WordNet   license wordnet

「a small unit serving as part of or as the nucleus of a larger political movement」
cadre

PrepTutorEJDIC   license prepejdic

「(刑務所の)『独房』;(修道院の)小さい独居室 / (ミツバチの)みつ房,巣穴 / 小さい部屋 / 『細胞』 / 電池 / 花粉室 / (共産党などの)細胞」


antigen」

  [★]

  • n.

WordNet   license wordnet

「any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)」

PrepTutorEJDIC   license prepejdic

「抗原(生物の体内にはいって免疫体を作る物質)」




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡